Literature DB >> 16254109

CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.

G M K Tse1, P-H Tan, T K F Ma, C B Gilks, C S P Poon, B K B Law.   

Abstract

BACKGROUND/AIMS: CD44s, the standard form of CD44, has been shown to be downregulated during malignant transformation of breast cancers. It has also been reported recently to be a useful marker in differentiating between benign and malignant papillary lesions of the breast, with high expression in the former. CD44s expression in benign and malignant papillary lesions was evaluated.
METHODS: CD44s expression was assessed by immunohistochemistry in 101 benign papillomas and 59 papillary carcinomas (seven invasive papillary carcinomas, 41 papillary ductal carcinomas in situ, and 11 ductal carcinomas involving papillomas).
RESULTS: Patients' age and tumour size were significantly different between the papilloma and papillary carcinoma groups (p < 0.0001). CD44s showed positive staining in 45 papillomas (45%) and five papillary carcinomas (8%), and the difference was significant (p < 0.0001). The myoepithelial cells, when present, were also positive for CD44s in both groups, with no observable differences. Using CD44s positive staining to differentiate between benign and malignant papillary lesions gives a sensitivity, specificity, and accuracy of 45%, 92%, and 62%, respectively.
CONCLUSIONS: CD44s may be useful as an adjunct in the evaluation of morphologically problematic cases of papillary lesion of the breast.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254109      PMCID: PMC1770758          DOI: 10.1136/jcp.2005.026906

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  33 in total

1.  Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast.

Authors:  H S Berner; J M Nesland
Journal:  Breast Cancer Res Treat       Date:  2001-01       Impact factor: 4.872

2.  CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma.

Authors:  N Guriec; L Marcellin; B Gairard; H Caldéroli; A Wilk; R Renaud; J P Bergerat; F Oberling
Journal:  Clin Exp Metastasis       Date:  1996-10       Impact factor: 5.150

3.  Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns.

Authors:  W Boecker; H Buerger; K Schmitz; I A Ellis; P J van Diest; H P Sinn; J Geradts; R Diallo; C Poremba; H Herbst
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

4.  Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma.

Authors:  T Masaki; A Goto; M Sugiyama; H Matsuoka; N Abe; A Sakamoto; Y Atomi
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

5.  Epitheliosis of the breast. An immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast.

Authors:  U Raju; J D Crissman; R J Zarbo; C Gottlieb
Journal:  Am J Surg Pathol       Date:  1990-10       Impact factor: 6.394

6.  Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.

Authors:  H S Berner; Z Suo; B Risberg; K Villman; M G Karlsson; J M Nesland
Journal:  Histopathology       Date:  2003-06       Impact factor: 5.087

7.  Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters.

Authors:  P A Regidor; R Callies; M Regidor; U Günthert; M Zöller; A E Schindler
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

8.  Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44.

Authors:  H P Sinn; K H Heider; P Skroch-Angel; G von Minckwitz; M Kaufmann; P Herrlich; H Ponta
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  Gains and losses of CD44 expression during breast carcinogenesis and tumour progression.

Authors:  A Bànkfalvi; H J Terpe; D Breukelmann; B Bier; D Rempe; G Pschadka; R Krech; W Böcker
Journal:  Histopathology       Date:  1998-08       Impact factor: 5.087

10.  CD44H regulates tumor cell migration on hyaluronate-coated substrate.

Authors:  L Thomas; H R Byers; J Vink; I Stamenkovic
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

View more
  6 in total

1.  CD44 expression in intraoral salivary ductal papillomas and oral papillary squamous cell carcinoma.

Authors:  Sarah G Fitzpatrick; Lindsay J Montague; Donald M Cohen; Indraneel Bhattacharyya
Journal:  Head Neck Pathol       Date:  2012-11-13

2.  The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.

Authors:  G M K Tse; P-H Tan; P C W Lui; C B Gilks; C S P Poon; T K F Ma; B K B Law; W W M Lam
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

3.  Immunoprofile from tissue microarrays to stratify familial breast cancer patients.

Authors:  Laura Schirosi; Simona De Summa; Stefania Tommasi; Angelo Paradiso; Domenico Sambiasi; Ondina Popescu; Giovanni Simone; Anita Mangia
Journal:  Oncotarget       Date:  2015-09-29

Review 4.  Novel CD44-downstream signaling pathways mediating breast tumor invasion.

Authors:  Allal Ouhtit; Balsam Rizeq; Haissam Abou Saleh; Md Mizanur Rahman; Hatem Zayed
Journal:  Int J Biol Sci       Date:  2018-10-05       Impact factor: 6.580

5.  CD133, but Not CD44, May Serve as a Novel Biomarker for Differential Diagnosis Between Basal Cell Carcinoma and Trichoblastomas.

Authors:  Yalan Bi; Xiaohua Shi; Dian Chen; Yi Zhao
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-02

6.  Collagen Type XI Alpha 1 Expression in Intraductal Papillomas Predicts Malignant Recurrence.

Authors:  Javier Freire; Lucia García-Berbel; Pilar García-Berbel; Saray Pereda; Ainara Azueta; Pilar García-Arranz; Ana De Juan; Alfonso Vega; Ángela Hens; Ana Enguita; Pedro Muñoz-Cacho; Javier Gómez-Román
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.